Primary Hyperoxaluria – Pipeline Review, H2 2017

Global Markets Direct’s, ‘Primary Hyperoxaluria – Pipeline Review, H2 2017’, provides an overview of the Primary Hyperoxaluria pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Primary Hyperoxaluria, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Primary Hyperoxaluria and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Primary Hyperoxaluria

The report reviews pipeline therapeutics for Primary Hyperoxaluria by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Primary Hyperoxaluria therapeutics and enlists all their major and minor projects

The report assesses Primary Hyperoxaluria therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Primary Hyperoxaluria

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Primary Hyperoxaluria

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Primary Hyperoxaluria pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Allena Pharmaceuticals Inc

Alnylam Pharmaceuticals Inc

Dicerna Pharmaceuticals Inc

Intellia Therapeutics Inc

OxThera AB

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Primary Hyperoxaluria - Overview

Primary Hyperoxaluria - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Primary Hyperoxaluria - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Primary Hyperoxaluria - Companies Involved in Therapeutics Development

Allena Pharmaceuticals Inc

Alnylam Pharmaceuticals Inc

Dicerna Pharmaceuticals Inc

Intellia Therapeutics Inc

OxThera AB

Primary Hyperoxaluria - Drug Profiles

ALLN-177 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ALLN-230 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ALN-GO1 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DCR-PHXC - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Oligonucleotides for Primary Hyperoxaluria - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Oxabact - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Primary Hyperoxaluria - Dormant Projects

Primary Hyperoxaluria - Discontinued Products

Primary Hyperoxaluria - Product Development Milestones

Featured News & Press Releases

Jul 27, 2017: European Commission Grants Orphan Drug Designation to Allena Pharmaceuticals Investigational Therapy for the Treatment of Primary Hyperoxaluria

Jul 17, 2017: Dicerna Expands Lead GalXC Development Program to Encompass All Forms of Primary Hyperoxaluria (PH) and Reveals New Therapeutic Target for DCR-PHXC

Jul 13, 2017: FDA Grants Orphan Drug Designation to Allena Pharmaceuticals’ Investigational Therapy for the Treatment of Primary Hyperoxaluria

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Primary Hyperoxaluria, H2 2017

Number of Products under Development by Companies, H2 2017

Products under Development by Companies, H2 2017

Number of Products by Stage and Target, H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Primary Hyperoxaluria – Pipeline by Allena Pharmaceuticals Inc, H2 2017

Primary Hyperoxaluria – Pipeline by Alnylam Pharmaceuticals Inc, H2 2017

Primary Hyperoxaluria – Pipeline by Dicerna Pharmaceuticals Inc, H2 2017

Primary Hyperoxaluria – Pipeline by Intellia Therapeutics Inc, H2 2017

Primary Hyperoxaluria – Pipeline by OxThera AB, H2 2017

Primary Hyperoxaluria – Dormant Projects, H2 2017

Primary Hyperoxaluria – Discontinued Products, H2 2017

List of Figures

List of Figures

Number of Products under Development for Primary Hyperoxaluria, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products by Routes of Administration, H2 2017

Number of Products by Stage and Routes of Administration, H2 2017

Number of Products by Molecule Types, H2 2017

Number of Products by Stage and Molecule Types, H2 2017

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports